

Mutations in the “a” Determinant Region of Hepatitis B Virus Genotype A among Voluntary Kenyan Blood Donors

Ednah K. Nyairo^{1,2*} Zipporah Ng'ang'a² James Kimotho,³ Samoel A. Khamadi³ Lihana Raphael³

Missiani Ochwoto³ Keith Talaam³ Joseph Mwangi^{3,1} Raphael Lwembe³

1. Institute of Tropical Medicine and Infectious Diseases P.O BOX 54840-00200, Nairobi, Kenya

2. Jomo Kenyatta University of Agriculture and Technology P.O Box 62000-00200, Nairobi, Kenya

3. Kenya Medical Research Institute P.O BOX 54840-00200, Nairobi, Kenya

Abstract

Occurrence of mutations within the major antigenic alpha determinant region of hepatitis B surface antigen (HBsAg) can alter HBV antigenicity resulting in failures in diagnosis, vaccine and hepatitis B immunoglobulin therapy. This study aimed at detection of mutations in the “a” determinant region of HBV surface antigen among voluntary blood donors in Kenya. This was a cross sectional study involving serology and molecular techniques. This study involved analysis of samples from blood transfusion centers. A total of 301 blood samples from donor blood were collected for the study. Sero-status for HBsAg was determined using Enzyme-Linked Immunosorbent Assay (ELISA). A fragment of the S gene including the “a” determinant was amplified by PCR from the HBsAg positive samples and sequenced for mutation analysis. Mutations and phylogenetic analyses were performed using Mega 6 software, Bioedit software and GENETYX[®] software version 9.1.0. Out of the 301 samples tested 69/301 (22.9%) were Polymerase Chain Reaction (PCR) positive including 2/69(2.9%) were sero-negative for HBsAg. All isolates were genotype A, sub-genotype A1. A total of 29 mutations were observed of which 37.9% were located within the “a” determinant. Mutations T143M and K122R were the most frequent in this study. Escape mutations associated with diagnostic failure, vaccine and immunoglobulin therapy escape were also identified. These findings are important for policies related to vaccine implementation and therapeutic and diagnostic guidelines.

Keywords: Escape mutants, genotype, hepatitis B virus, antigenic determinant, surface antigen

1. Introduction

Hepatitis B virus infection (HBV) is a major public health concern especially in Africa, Middle East and Asia (Akbar *et al.*, 2004, McMahon, 2005). More than 4 billion people have had contact with HBV worldwide (Ying-Hui, 2012). Of these, about 360 million people are chronic carriers of HBV that can cause death from liver cirrhosis and hepatocellular carcinoma (HCC) (Lavanchy, 2004; WHO, 2015).

Though HBV is a DNA virus, it replicates via reverse transcriptase (polymerase enzyme) which has no proof-reading activity leading to the generation of mutations occurring naturally during infections (Kramvis 2014).

Hepatitis B surface antigen (HBsAg) is a primary target for diagnosis and immunoprophylaxis of HBV infection (El-sherif *et al.*, 2007). The HBsAg which is a 226 amino acid sequence contains a highly conformational, hydrophilic domain known as the “a” determinant located at positions between aa124-aa147 within the Major Hydrophilic Region (MHR; aa110-aa165) (Hu *et al.*, 2009). The dominant epitopes of “a” determinant are the targets of neutralizing antibodies used in active, passive immunization and in diagnostic assays. (Kay *et al.*, 2007). Mutations in this region can reduce the binding affinity between the HBsAg and antibody to the HBsAg resulting in weak reactivity of serological assays. Although, mutations have been described in all the four open reading frames (ORFs) of the HBV, S escape mutants is the most worrying since it may be spread by blood transfusion. HBV DNA detection by nucleic acid amplification technology (NAT) is not mandatory for blood donor screening in many countries, especially in those areas where the prevalence of S escape mutants is projected to be high (Fischinger *et al.*, 2010). It is imperative that the prevalence and types of variants of the “a” determinant found in the population be monitored, because this will affect policy decisions relating to vaccine and diagnostic reagents design (Zuckerman, 2000; Francois *et al.*, 2001). To date cases of blood donations with diagnostic escape mutations not detected by HBsAg screening assay have been reported (Levicnic, 2004). Therefore, we aimed at detection of mutations in the “a” determinant region within the S gene among voluntary blood donors in Kenya.

2. Methods

This study was cross-sectional where 301 plasma samples were collected from blood transfusion centers in Kenya. The samples were then transported to Kenya Medical Research Institute (KEMRI) HBV laboratory through cold chain and stored at -80°C till use. The presence of HBsAg was tested using Hepanostika *HBsAg Ultra* (BioMérieux, Lyon, France) kit as per the manufacturer’s instructions.

Viral DNA was extracted from 200µl aliquoted plasma using a QIAamp DNA Mini Kit (QIAGEN, Hilden, Germany) according to the manufacturer's instructions. Extracted DNA was eluted in 60µl DNase free water and stored at -20°C till use. A 780 base pair (bp) fragment of HBV was amplified by nested PCR using Kentaq DNA polymerase kit from Kenya and HBV specific primer pair S1(LLf) 5'-TCCTGCTGGTGGCTCCAG-3' as sense primer and S1(LLr) CGTTGACATACTTTCCAATCAA-3' as anti-sense primer (Osilowy et al., 2009). Nested PCR was performed by an ABI Thermocycler 9600 system (Applied Biosystems, USA). The conditions for first round PCR consisted of 94 °C for 5 min; followed by 40 cycles at 94 °C for 4 min; 94 °C for 45 seconds min; and 46 °C for 30 seconds; and final extension at 72 °C for 10 min. A total volume of 25µL was amplified in first-round, containing QIAGEN PCR buffer, 0.5µM of each primer, 0.2 mM dNTP mix, 2.5 U *Taq* polymerase (KEMRI *Taq*) and 10µL of extracted DNA. The second PCR round was done under the same conditions except that annealing was done at 50°C with 10µl of the first-round product using the primer S2nLLf 5'- ACCCTGYRCCGAACATGGA-3' as sense primer and S2 nLLr) 5'-CAACTCCCAATTACATARCCCA -3' as anti-sense primer (Osilowy *et al.*, 2009). PCR-amplified products (10 µl) were separated by electrophoresis on 2% agarose gel, stained with ethidium bromide and viewed under ultraviolet light.

HBV DNA positive samples were sequenced using a big dye terminator and the obtained nucleotide sequences edited and aligned using BioEdit sequence alignment editor software version 5.0.9 (Hall, 1999). The newly sequenced (query sequences) were aligned along with reference sequences available in the genbank. This was followed by CLUSTAL W multiple sequence alignment (Thompson, 1994). After some manual editing by stripping the ends the phylogenetic and molecular evolutionary analyses were conducted using MEGA6 (Tamura *et al.*, 2013). The Neighbour-Joining method on the MEGA programme was used to generate a bootstrap consensus phylogenetic tree out of a 1000 bootstrap replicates. The nucleotide sequences detected in this study were deposited in the GenBank and these are their accession numbers (KR816101-KR816152). The aligned nucleotide sequences were translated into amino acid sequences using GENETYX® software version 9.1.0. to allow for determination of any mutations within the S protein.

Approval to conduct the study was granted by Kenya Medical Research Institute (Kemri) Scientific and Ethics Review Unit (SERU) (SSC NO. 2443) and Regional Blood Transfusion Centre.

3. Results

Hepatitis B Virus DNA PCR was done in 301 samples; PCR amplified 69(22.9%) samples. Of these 2 (2.9%) were sero-negative for HBsAg. Table 1 summarizes the ELISA and PCR results.

The PCR products obtained were sequenced and 52 (75 %) successfully genotyped. A phylogenetic tree was generated for all 52 nucleotide sequences as shown in Figure 1. The predominant genotype was A.



Figure 1: Phylogenetic analysis based on nucleotide sequencing of the S region. The tree contains sequences from 52 samples and a set of representative sequences belonging to genotypes and subgenotypes retrieved from Genbank. The phylogenetic tree was constructed using the neighbor-joining method in Clustal W.

3.1 Prevalence of HBV Escape Mutations

A total 29 mutations were observed in the present study. Eleven of the 29 mutations (37.9%) were located within the “a” determinant (124-147), whereas 63.6% (7/11) were in the first loop (positions 120-137) and 36.4% (4/11) in the second loop (positions 139-147). The amino acid substitutions detected in the “a” determinant of HBsAg included mutations at positions M133I, K133E, M134S, and F137L and T143M in 5 sequences. The most frequent mutations observed were T143M and K122R detected each in (3/52) 5.8% of sequences.

Changes in the Nucleotide and Amino Acid Sequences in the ‘a’ Determinant Region of the HBV S Gene. Dots indicate identity to the genotype A consensus.



Twenty sequences (38.5%) had amino acid changes outside the ‘a’ determinant identified among them; Y161F, E164G W165L, S167L, V184A, T189I, S193L and A194V. In addition 13 had a single mutation (65.0%), 7(35%) had double to triple mutations.

Table 2: Distribution of amino acid substitutions in the HBV S gene sequences.

| Amino acid position | Wild type amino acid | mutation | Frequency |
|---------------------|-----------------------------|------------------|-----------|
| 101 | Glutamine/Histidine(Q/H) | Histidine(H) | 1 |
| 114 | Threonine/Lysine(T/K) | Lysine(K) | 1 |
| 114 | Threonine/Serine(T/S) | Serine(S) | 1 |
| 118 | Threonine/Alanine(T/A) | Alanine(A) | 1 |
| 122 | Lysine/Arginine(K/R) | Arginine (R) | 3 |
| 130 | Glycine/Serine(G/S) | Serine(S) | 1 |
| 133 | Methionine/Isoleucine(M/I) | isoleucine(I) | 1 |
| 133 | Lysine/Glutamic Acid(K/E) | Glutamic acid(E) | 1 |
| 134 | Methionine/Serine(M/S) | serine(S) | 1 |
| 137 | Phenylalanine/Leucine(F/L) | Leucine(L) | 1 |
| 143 | Threonine/Methionine(T/M) | Methionine(M) | 3 |
| 146 | Asparagine/Lysine(N/K) | Lysine (K) | 1 |
| 149 | Cysteine/Arginine(C/R) | Arginine(R) | 1 |
| 159 | Alanine/Valine(A/L) | Valine(V) | 1 |
| 161 | Tyrosine/Phenylalanine(Y/F) | Phenylalanine(F) | 1 |
| 164 | Glutamic Acid/Glycine(E/G) | Glycine(G) | 1 |
| 165 | Tryptophan/Leucine(W/L) | Leucine(L) | 1 |
| 167 | Serine/Leucine(S/L) | Leucine(L) | 2 |
| 184 | Valine./Alanine(V/A) | Alanine(A) | 2 |
| 189 | Threonine /Isoleucine(T/I) | Isoleucine(I) | 1 |
| 193 | Serine/Leucine(S/L) | Leucine(L) | 1 |
| A194 | Alanine/Valine(A/V) | Valine(V) | 1 |

4. Discussion

In this study we report on HBsAg mutations and HBV genotypes among voluntary blood donor population in Kenya. Genotype A sub-genotype A1 was observed in all the HBV DNA positive plasma samples tested. This was comparable with other published data in Kenya (Kwange *et al.*, 2013). Genotype A was found to be

predominant in Kenya followed by genotypes E and D (Mwangi *et al.*, 2008; Ochwoto *et al.*, 2013). This probably suggest the trends in HBV genotypes has remained the same especially in this study population

This study also identified mutations of interest in HBV genome. Vaccine escape, immunotherapy and diagnostic escape mutants within and outside the “a” determinant region of HBsAg were both detected among the volunteer blood donor population. Since the basis for effective prevention of HBV infections lies in the use of effective vaccination and diagnostic programming, results of this study therefore provides relevant and valuable information on genetic variability of HBV.

This study found different mutations in the S region of HBV genomes, where the percentage of samples with these mutations was 29/52(42.3%).

In comparison to studies that have been conducted in Kenya Kwange *et al.*, 2013 reported S gene mutations including K122R, T189I and S210R in samples collected from various parts of the country. However, they did not report any amino acid substitution in “a” determinant. Our finding showed that 37.9% mutations were located within the “a” determinant 124-147.

In a study carried out in Iran (Moradi *et al.*, 2012) the following amino acid changes were reported in genotype D: Y100F, L109R, I110L, G112R, S117I, P120S/T, R122K/T, M133I, Y134H, T140I, S143L, G145R, G159R, and E164V. Five of 40 mutations (12.5%) occurred in “a” determinant region and they included; M133I, Y134H in the first loop of “a” determinant and the rest of substitutions including T140I, S143L and G145R occurred in the second loop of “a” determinant. In this study 11 of the 29 mutations (37.9%) were located within the “a” determinant, 63.6% (7/11) in the first loop (amino acid positions 120-137) and 36.4% (4/11) in the second loop (amino acid positions 139-147).The only similarity that is seen between the two studies is amino acid substitutions at M133I which is associated with vaccine escape. The differences might be attributed to the difference in genetic variability of HBV.

Our study reported a pattern of more frequent mutations including K122R and T143M. A mutation K122R substitution was detected in three samples within the MHR (aa110-aa165) this is a polymorphism typically linked with determining *d/y* sub-serotype specificity (Martin *et al.*, 2010 ;Amponsah *et al.*, 2013). Two previous studies in Kenyan; one by Ochwoto *et al.*, (2013), conducted among liver disease patients and that of Kwange *et al.*, 2013 among a blood donor population reported mutations in HBV genome. The current study, however reports diversity of mutations within a larger study population and diverse geographical localities in Kenya.

Moreover, Yong *et al.*, 2012 reported mutations at positions D99N, Y100F, Q101R/H, L110I, T113S, S114T, S117T, T118M, I126T/V, W165L, and V168A. Our findings showed different feature of mutations with four similar mutations at positions Q101H, K122R, T143M, and W165L. This difference could be due to high variability of geographical location.

A known mutation T143M frequent in this study was reported in Indonesian blood donors and has been associated with altering antigenic properties of variant HBsAg, this mutant also has been associated with problems in diagnostic assays and escape to vaccine and HBIG therapy as reported by Le *et al.*, 2010. Here, T143M was found in 3 out of 52 samples. Among these samples, two samples were sero-negative for HBsAg but positive for the corresponding HBV- DNA. Repeat testing of these samples consistently gave negative results despite using different test kits including ELISA and rapid tests. In addition these samples were observed to have mutations; T143M, M133I respectively. Since these substitutions has been associated with failure of HBIG therapy and problems in detection assays (Ren *et al.*, 2006). It is likely that failure to detect positivity by serology on the samples could be due to mutations. Such reports of false-negative diagnostic results due to HBsAg mutants have been described previously (Coleman, 2006; Rebecca, 2011).This could also be due to low concentration of analyte. We however did not carry out viral load testing due to unavailability of resources.

Mutation M133I observed in the present study in one sample was reported in a Spanish study and is associated with the failure of HBIG therapy since it causes a reduced HBsAg affinity to anti-HBs and reduced HBsAg detection in commercial diagnostic assays (Le *et al.*2010). Other different amino acid substitutions G130S, F137L, T114S, T114K and M134S within MHR were also found in the samples from HBV subtype A1. The effects of these variations on the HBsAg are unknown. The other important finding in the current study is the magnitude of mutations. In total, 29 mutations were detected in 20 of the 52 samples analyzed. These mutations were distributed across the sequenced genome fragment including 11 of 29 in ‘a’ determinant, 7 and 4 of 11 in the first and second loop respectively. Since these samples were collected from across different sites in Kenya, this probably demonstrates an underlying genotypic mutation dynamics of HBV occurrence in the population. The major concern arising from HBsAg mutations is the 3 clinical related outcomes which includes; diagnostic escape mutants affecting reliability of results of various diagnostic assays, escape from vaccine-induced immunity, antiviral resistance and passively transferred neutralizing responses in newborn babies or liver-transplant recipients (Sayiner *et al.*,2007;Ma, and Wang, 2012). Considerably, these events could be taking place in our population undetected, except for blood transfusion, work place, and infants’ vaccination; there is no universal policy on HBV prevention in Kenya. This situation could be similar in most countries across Africa.

Both genotype variability and mutations are important consideration in development of effective vaccines. Hepatitis B virus has been shown to display a certain geographical distribution. Our study however indicates a single genotype on all the samples collected from different regions in Kenya. This is however understandable since genotype A has been shown to be the most prevalent. Whereas genotypes have been shown to influence the disease progression and treatment responses (Bartholomeusz and Schaefer, 2004; Chotiyaputta and Lok, 2009). A strong link between HBV genotype and the natural history of disease as well as the better response to interferon treatment in genotype A is encouraging. Given the high prevalence of HBV in Kenya, and in Africa, where blood transfusion is a critical intervention monitoring and prevention of infections is crucial. While mutations in the major hydrophilic region of HBV Surface antigen have been reported in developing countries, largely, there is limited data on Hepatitis B in Kenya partly due to lack of official programming, universal testing strategy and prioritized research. Currently, the public health impact of Hepatitis is drawing attention and the future is likely to see more efforts and focused momentum towards hepatitis. Availability of information on mutations and genetic variants of HBV in this region is required to inform development of clinical and surveillance mechanisms.

5. Conclusions

Genotypes A, sub-genotype A1 was found to be prevalent. Escape mutations which have been associated with diagnostic failure, vaccine escape and immunoglobulin therapy are present within the population. Other than T143M, different aa substitutions G130S, F137L, T114S, T114K and M134S within MHR were also found in the samples from HBV subtype A1. The effects of these variations on the HBsAg are unknown and there is need for further studies. This finding is an important monitoring tool in guiding future policies related to laboratory diagnostic procedures.

6. Acknowledgements

We wish to acknowledge the support of the Director Kenya National Blood Transfusion Services for providing samples for the study and KEMRI Production Department staff for their support during the study.

References

- Akbar, S. Furukawa, N. Horiike, M. and Onji, V. (2004). Vaccine therapy for hepatitis b virus. *Curr. Drug Target Infect*, 4(2):93–101.
- Bartholomeusz, A. and Schaefer, S. (2004). Hepatitis B virus genotypes: Comparison of genotyping methods. *Med Virol*, 14:3-16.
- Norouzi, M. et al., (2010). Hepatitis B virus surface antigen variants clustered within immune epitopes in chronic hepatitis B carriers from Hormozgan Province, south of Iran. *Iran. J. Basic Med. Sci.*, 13(4), 213-224.
- Chotiyaputta, W. and Lok, A.S. (2009). Hepatitis B virus variants. *Gastroenterol Hepatol*, 6:453-462.
- Chu, C.J., Keeffe, E.B., Han, S.H., Perrillo, R.P., Min, A.D., Soldevila-Pico, C., Carey, W., Brown, R.S.Jr, Luketic, V.A., Terrault, N. and Lok, A.S. (2003). Hepatitis B virus genotypes in the United States: Results of a nationwide study. *Gastroenterology*, 125:444–451.
- Coleman Paul F. (2006) Detecting hepatitis B surface antigen mutants. *Emerg Infect Dis*, 12:198-203.
- Amponsah-Dacosta, Ramokone L. Lebelo, Nare J. Rakgole, Rosemary J. Burnett, Selokela G. Selabe, M. Jeffery Mphahlele. Health facility-based study to assess population immunity and chronic carriage to HBV after nearly two decades of universal hepatitis B immunization in South Africa. In preparation 2013.
- El-Sherif, A.M., Abou-Shady, M.A., Al-Hiatmy, M.A., Al-Bahrawy, A.M. and Motawea, E.A. (2007). Screening for hepatitis B virus infection in Egyptian blood donors negative for hepatitis B surface antigen. *Hepato Int*, 1:469-70.
- Fischinger JM, Stephan B, Wasserscheid K, Eichler H, Gartner BC: A (2010) Cost benefit analysis of blood donor vaccination as an alternative to additional DNA testing for reducing transfusion transmission of hepatitis B virus. *Vaccine* 28(49):7797-7802.
- François, G., Kew, M., Van Damme, P., Mphahlele, M.J. and Meheus, A. (2001). Mutant hepatitis B viruses: a matter of academic interest only or a problem with far-reaching implications? *Vaccine*, 19: 3799-3815 [PMID: 11427251]
- Hall T.A. 1999. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. *Nucl. Acids. Symp. Ser.* 41:95-98.
- Horvat Rebecca T. (2011) Diagnostic and Clinical Relevance of HBV Mutations. *Labmedicine Volume 42 Number 8 August*
- Hu XB, Yue QH, Zhang XQ, Xu XQ, Wen Y, Chen YZ, Cheng XD, Yang L, Mu SJ: Hepatitis B virus genotypes and evolutionary profiles from blood donors from the northwest region of China. *Virol J* 2009, 6:199
- Hunt, C.M., McGill, J.M., Allen, M.I. and Condreay, L.D. (2000). Clinical relevance of hepatitis B viral mutations. *Hepatology*, 31:1037-1044.

- Kramvis A. (2014) Genotypes and genetic variability of hepatitis B virus. *Intervirology*. 57(3–4):141–50.
- Kramvis, A. and Kew, M.C. (2007). Epidemiology of hepatitis B virus in Africa, its genotypes and clinical associations of genotypes. *Hepatology Res*, 37: S9-S19.
- Lavanchy, D. (2004). Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. *J Viral Hepat*; 11(2):97-107.
- Levicnik, S.(2004) Hepatitis B surface antigen escape mutant in a first time blood donor potentially missed by a routine screening assay. *Clin Lab* 50(1-2):49-51
- Locarnini, S. (2004). Molecular Virology of Hepatitis B Virus. *Seminars in liver disease/volume 24, supplement 1*.
- Locarnini, S., McMillan, J. and Bartholomeusz, A. (2003). The hepatitis B virus and common mutants. *Semin Liver Dis*, 23:5-20.
- Lule G.N and Nyawira B. (2014). Guidelines for the Treatment of Chronic Hepatitis B and C Viral Infections in Kenya. *Gastroenterology Society of Kenya*.
- McMahon, B. J. (2009). The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B. *Hepatology Int*, 3:334–342.
- McMahon, B.J. (2005). Epidemiology and natural history of hepatitis B. *Semin. Liver Dis*, 25:3-8.
- Moradi A, Zhand S, Ghaemi A, Javid N, Tabarraei A. (2012). Mutations in the S gene region of hepatitis B virus genotype D in Golestan Province-Iran. *Virus Genes*. 44(3):382-7
- Mutuma, G.Z., Mbuchi, M.W., Zeyhle, E., Fasana, R., Okoth, F.A, Kabanga J.M., Kuria, J., Shiramba, L., Njenga, M.K., Kaiguri, P.M. and Osidiana, V. (2011). Prevalence of Hepatitis B Virus (HBV) surface antigen and HBV associated hepatocellular carcinoma in Kenyans of various ages. *Afr J Health Sci.*, 18:53-61
- Mwangi, J., Nganga, Z., Songok, E., Kinyua, J., Lagat, N., Muriuki, J., Lihana, R., Khamadi, S., Osman, S., Lwembe, R., Kiptoo, M., Mwau, M., Chirchir, R., Mpoke, S., Nyamongo, J., Okoth, F., Yamada, R., Kageyama, S. and Ichimura, H. (2008). Molecular genetic diversity of hepatitis B virus in Kenya. *Intervirology*, 51(6):417-21.
- Ochwoto, M., Chauhan, R., Gopalakrishnan, D., Chen, C., Ng'ang'a, Z., Okoth, F., Kioko, H., Kimotho, J., Kaiguri, P. and Kramvis, A. (2013). Genotyping and molecular characterization of hepatitis B virus in liver disease patients in Kenya. *Infection, Genetics and Evolution*, 20:103–110
- Rebecca T. Horvat (2011). Diagnostic and Clinical Relevance of HBV Mutations(2011). PhD, D(ABMM)
- Said, Z.N., Sayed, M.H., Salama, II., Aboel-Magd, E.K., Mahmoud, M.H., Setouhy, M.E., et al. (2013). Occult hepatitis B virus infection among Egyptian blood donors. *World J Hepatol*, 5:64-73.
- Sayan M., Senturk O., Akhan S.C., Hulagu S., Cekmen M.B (2010). Monitoring of hepatitis B virus surface antigen escape mutations and concomitantly nucleos(t)ide analog resistance mutations in Turkish patients with chronic hepatitis B. *International Journal of Infectious Diseases* 14S, e136–e141.
- Sayiner AA, Agca H, Sengonul A, Celik A, Akarsu M. (2007). New hepatitis B virus vaccines escape mutation in a renal transplant recipient. *J Clin Virol* 38:157–160.
- Susan I Ie, Meta D Thedja, Martono Roni, David H Muljono Ie et al.(2010) Prediction of conformational changes by single mutation in the hepatitis B virus surface antigen (HBsAg) identified in HBsAg-negative blood donors *Virology Journal* 2010, 7:326
- Suzuki, Y., Kobayashi, M., Ikeda, K., Suzuki, F., Arfase, Y., Akuta, N., Hosaka, T., Saitoh, S., Someya, T., Matsuda, M., Sato, J., Watabiki, S., Miyakawa, Y. and Kumada, H. (2005). Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan. *J Med Virol*, 76:33-39.
- Tamura K, Stecher G, Peterson D, Filipinski A, and Kumar S (2013) MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. *Molecular Biology and Evolution*:30 2725-2729.
- Thompson, J.D., Higgins, D.G. and Gibson, T.J. (1994) CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position specific gap penalties and weight matrix choice. *Nucleic Acids Research*, submitted, June 1994.
- Tian, Y., Xu, Y., Zhang, Z., Meng, Z., Qin, L., Lu, M. and Yang D. (2007). The amino Acid residues at positions 120 to 123 are crucial for the antigenicity of hepatitis B surface antigen. *J Clin Microbiol*, 45:2971-2978.
- Weinberger, K., Bauer, T., Bohm, S. and Jilg, W. (2000). High genetic variability of the group-specific a-determinant of hepatitis B virus surface antigen (HBsAg) and the corresponding fragment of the viral polymerase in chronic virus carriers lacking detectable HBsAg in serum. *J Gen Virol*, 81:1165–74.
- WHO (2015). Hepatitis B. World Health Organization Fact sheet No. 204.
- WHO-World Health Organization (2004). Hepatitis B vaccines. *Wkly Epidemiol Rec*, 79: 255-263.
- Wu C, Zhang X, Tian Y, Song J, Yang D, Roggendorf M, Lu M, Chen X. (2010). Biological significance of amino acid substitutions in hepatitis B surface antigen (HBsAg) for glycosylation, secretion, antigenicity and immunogenicity of HBsAg and hepatitis B virus replication. *J Gen Virol* 91:483–4492.

- Zuckerman, A.J. (2000). Effect of hepatitis B virus mutants on efficacy of vaccination. *Lancet*; 355: 1382-1384
- Liu CJ, Kao JH, Shau WY, Chen PJ, Lai MY, Chen DS(2002). Naturally occurring hepatitis B surface gene variants in chronic hepatitis B virus infection: Correlation with viral serotypes and clinical stages of liver disease. *J Med Virol.* 2002;68:50–9
- Kay A, Zoulim F (2007) .Hepatitis B virus genetic variability and evolution. *Virus Res.*;127(2):164–76
- Martin MC, Welge JA, Shire NJ, Rouster SD, Shata MT, Sherman KE, Blackard JT (2010). Genomic variability associated with the presence of occult hepatitis B in HIV co-infected individuals. *J Viral Hepat*; 17:588-597.
- Ren FR, Tsubota A, Hirokawa T, Kumada H, Yang ZH, Tanaka H(2006). A unique amino acid substitution, T126I, in human genotype C of hepatitis B virus S gene and its possible influence on antigenic structural change. *Gene* 2006, 383:43-51.